Germany· DE-A57-162b08ab3f0a8127
Sirolimus Panacea Biotec
A sirolimus product containing sirolimus, registered in Germany by Panacea Biotec Germany Gmbh. The same ATC class is registered in 13 of our 19 countries.
Checked against EMA Article 57 (European Union) on
Informational only — not a medical device.
Where it is registered
Sirolimus is registered in 13 of 19 countries.
Countries holding a registration under ATC L04AH01 (sirolimus), each read from that country’s own register.
- This record: Germany, from EMA Article 57 (European Union)
- 8 of them publish a price we can compare per daily dose
Sirolimus · ATC L04AH01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Germany
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of sirolimus costs, country by country.
Normalised to the WHO defined daily dose (3 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Sirolimus · price per daily dose (3 mg)
USD · FX 28 Sept 2026
- CH Switzerland$18.00
The record
At a glance
EMA Article 57 (European Union)- Active substance
- Sirolimus
- Manufacturer
- Panacea Biotec Germany Gmbh
- Country
- Germany (DE)
- ATC code
- L04AH01
- ATC class
- Sirolimus
- Defined daily dose
- 3 mg, O
- Reimbursed
- Not published by this register
- Source register
- EMA Article 57 (European Union)
- Last checked
- September 30, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
737 interactions on record for sirolimus.
Graded by severity as the source publishes them — 162 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Sirolimus · interactions on record
737 records
- 162 severe
- 441 moderate
- 8 minor
- 126 info
Most severe, free to view
- ClotrimazoleA01AB18severe
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Sirolimus in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesFYARROAadi Bioscience, Inc.
- United KingdomHyftor 2mg/g gelPlusultra Pharma UK Ltd
- CzechiaHYFTORPlusultra pharma GmbH, Düsseldorf
- IrelandHYFTOR 2 mg/g GelPlusultra Pharma GmbH
- SwitzerlandRapamune 0.5 mg, überzogene TablettenPfizer AG
- FinlandHyftorPlusultra Pharma GmbH
- SwedenHyftor 2 mg/g GelPlusultra pharma GmbH
- SpainRAPAMUNE 0,5 mg COMPRIMIDOS RECUBIERTOSPfizer Europe Ma Eeig
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hyftor, Rapamune
- Liechtenstein · Hyftor, Rapamune
- Norway · Hyftor, Rapamune
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of EMA Article 57 (European Union). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/20bad179-da3b-4125-8c60-2cbaa72bb38b GET /v1/drugs/20bad179-da3b-4125-8c60-2cbaa72bb38b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"pzn": null,
"route": "Oral Use",
"source": "ema_art57_de",
"ma_number": null,
"substance": "Sirolimus",
"atc_from_source": null,
"authorisation_country": "Germany"
}See everything about sirolimus.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.